AQST News and Press, Aquestive Therapeutics Inc. From 08/08/23

2023-08-08 10:45:02 ET Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Conference Call August 08, 2023, 08:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice Presiden...

2023-08-07 16:05:33 ET Aquestive Therapeutics press release ( NASDAQ: AQST ): Q2 GAAP EPS of -$0.10 beats by $0.01 . Revenue of $13.24M (-0.2% Y/Y) beats by $2.23M . For further details see: Aquestive Therapeutics GAAP EPS of -$0.10 beats by $0.01, revenu...

Submitted proposed pivotal trial protocol for Anaphylm™ (epinephrine) Sublingual Film to the FDA Submitted an NDA to the FDA for Libervant™ (diazepam) Buccal Film for patients between two and five years of age Reported 24% year-over-year growth in quarterly revenue adjusted ...

2023-08-06 17:35:20 ET Major earnings expected after the bell on Monday include: Palantir Technologies ( PLTR ) Lucid Group ( LCID ) Skyworks Solutions ( SWKS ) Beyond Meat ( BYND ) Paramount Global ( PARA ) For further details see: Notabl...

WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative product...

Reports positive topline data from latest pilot pharmacokinetic (PK) study Plans to submit pivotal PK clinical study protocol to the FDA in early August Anticipates commencement of its definitive pivotal PK clinical trial in the fourth quarter of 2023 WARREN, N.J., July 27...

2023-07-25 20:37:04 ET Summary Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/year market. Pharmacokinetic studies have shown faster onset of action and comparable serum levels o...

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative produc...

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative product...

WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative product...